Taysha Gene Therapies Inc. (TSHA) News

Taysha Gene Therapies Inc. (TSHA): $3.82

0.30 (+8.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TSHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter TSHA News Items

TSHA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TSHA News Highlights

  • TSHA's 30 day story count now stands at 9.
  • Over the past 10 days, the trend for TSHA's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • The most mentioned tickers in articles about TSHA are GENE, RARE and VG.

Latest TSHA News From Around the Web

Below are the latest news stories about Taysha Gene Therapies Inc that investors may wish to consider to help them evaluate TSHA as an investment opportunity.

Two Insider Moonshots Rising on Sudden Buying

Biotech insiders are among the most important investors to pay close attention to.

Thomas Yeung on InvestorPlace | February 10, 2022

The Independent Director of Taysha Gene Therapies, Inc. (NASDAQ:TSHA), Paul Manning, Just Bought 3.4% More Shares

Those following along with Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) will no doubt be intrigued by the recent...

Yahoo | February 10, 2022

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium

DALLAS, February 09, 2022--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the

Yahoo | February 9, 2022

Taysha Gene Therapies Inc. (TSHA) Recovers 20.85% From Low: Are We There Yet?

Taysha Gene Therapies Inc. (NASDAQ:TSHA) concluded the trading at $7.94 on Friday, February 04 with a rise of 2.06% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $7.78 with its price kept floating in the range of $7.80 and $8.9299 on Taysha Gene Therapies Inc. (TSHA) Recovers 20.85% From Low: Are We There Yet? Read More »

Stocks Register | February 5, 2022

Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy Trial

Taysha Gene Therapies Inc (NASDAQ: TSHA ) has reported clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg and long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy (GAN). 5-point improvement was observed in the rate of decline in MFM32 score for the high dose cohort compared to natural … Full story available on Benzinga.com

Benzinga | January 31, 2022

Taysha posts data from high dose cohort for TSHA-120 in giant axonal neuropathy

Announcing the data for high dose cohort of TSHA-120 in rare inherited disease, giant axonal neuropathy, Taysha Gene Therapies (TSHA) noted that the experimental therapy led to

Seeking Alpha | January 31, 2022

Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy

DALLAS, January 31, 2022--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported positive clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg, as well as long-term durability data across all therapeutic doses of TSHA-120 in gia

Yahoo | January 31, 2022

Taysha Gene Therapies (TSHA) Gets a Buy Rating from JMP Securities

In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $40.00. The company's shares closed last Thursday at $6.98. According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of 9.1% and a 33.3% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Crispr Therapeutics AG, and Intellia Therapeutics. Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $39.17, implying a 397.7% upside from current levels.

Howard Kim on TipRanks | January 27, 2022

Taysha Gene Therapies (TSHA) Gets a Buy Rating from Needham

In a report released today, Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $47.00. The company's shares closed last Thursday at $7.05. According to TipRanks.com, Blum 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -41.4% and a 5.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Crispr Therapeutics AG. Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $39.17, implying a 397.7% upside from current levels.

Christine Brown on TipRanks | January 27, 2022

8 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio

In this article, we will take a look at some of the stocks in Eashwar Krishnan’s Tybourne Capital Management portfolio. You can skip our detailed discussion and go to see 5 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio. Eashwar Krishnan serves as the portfolio manager at Tybourne Capital Management, an investment management firm based […]

Yahoo | January 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4985 seconds.